Introduction

Solid tumors are in a constant state of evolution with progressive heterogeneity [1,2]. The process of metastatic progression is accompanied by multiple phenotypic alternations that result in decreased adhesiveness and increased cellular motility among other alterations [3]. Some motile cancer cells have the capacity to disseminate to distant sites via the vasculature and lymphatic channels and invade tissue leading to formation of a metastatic lesion [4]. Circulating tumor cells (CTCs) thus form a key link between primary tumors and their distant metastases, demarcating irreversible progression of the disease. Isolation and characterization of these live and active cancer cells may improve disease prognosis, as has been demonstrated in prostate cancer (PCa) [5].

The shedding of CTCs is a dynamic process that occurs with both primary and metastatic tumors. The fact that disseminated tumor cells can be detected in the blood of PCa patients after prostatectomy [6] suggests that CTCs can be shed from either residual tumor in the prostate bed or from metastatic deposits. Molecular investigation of these cells may provide real-time information on the status of malignant progression. As the

Abstract

Tumor cells are inherently heterogeneous and often exhibit diminished adhesion, resulting in the shedding of tumor cells into the circulation to form circulating tumor cells (CTCs). A fraction of these are live CTCs with potential of metastatic colonization whereas others are at various stages of apoptosis making them likely to be less relevant to understanding the disease. Isolation and characterization of live CTCs may augment information yielded by standard enumeration to help physicians to more accurately establish diagnosis, choose therapy, monitor response, and provide prognosis. We previously reported on a group of near-infrared (NIR) heptamethine carbocyanine dyes that are specifically and actively transported into live cancer cells. In this study, this viable tumor cell-specific behavior was utilized to detect live CTCs in prostate cancer patients. Peripheral blood mononuclear cells (PBMCs) from 40 patients with localized prostate cancer together with 5 patients with metastatic disease were stained with IR-783, the prototype heptamethine cyanine dye. Stained cells were subjected to flow cytometric analysis to identify live (NIR+) CTCs from the pool of total CTCs, which were identified by EpCAM staining. In patients with localized tumor, live CTC counts corresponded with total CTC numbers. Higher live CTC counts were seen in patients with larger tumors and those with more aggressive pathologic features including positive margins and/or lymph node invasion. Even higher CTC numbers (live and total) were detected in patients with metastatic disease. Live CTC counts declined when patients were receiving effective treatments, and conversely the counts tended to rise at the time of disease progression. Our study demonstrates the feasibility of applying of this staining technique to identify live CTCs, creating an opportunity for further molecular interrogation of a more biologically relevant CTC population.

Citation: Shao C, Liao C-P, Hu P, Chu C-Y, Zhang L, et al. (2014) Detection of Live Circulating Tumor Cells by a Class of Near-Infrared Heptamethine Carbocyanine Dyes in Patients with Localized and Metastatic Prostate Cancer. PLoS ONE 9(2): e88967. doi:10.1371/journal.pone.0088967

Editor: Joseph Najbauer, University of Pécs Medical School, Hungary

Received September 19, 2013; Accepted January 14, 2014; Published February 14, 2014

Copyright: © 2014 Shao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by research grants from the Prostate Cancer Foundation, National Institutes of Health/National Cancer Institute (2PO1CA098912 and 1RO1CA122602) and the Board of Governors Cancer Research Chair (LWKC), and by the Program of International Science and Technology Cooperation of China (No. 2011DFA33110). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors declare that no competing interests exist.

* E-mail: Edwin.Posadas@scmc.edu (EMP); Ruoxiang.wang@csghs.org (RW); Leland.chung@csghs.org (LWKC)

† These authors contributed equally to this work.
collection of CTCs typically requires low-volume standard phlebotomy, some have proposed that CTCs may be exploited as an ideal surrogate tissue or liquid biopsy to gauge disease status [7]. Such a source of tissue would provide a simple, minimally-invasive tissue source that could be accessed serially to provide high temporal definition of the evolution of underlying disease. The predictive value of CTCs relies on technical advances to enable reliable detection and isolation. CTCs constitute only a minute fraction of peripheral blood mononuclear cells (PBMCs). Many new technologies are presently being tested for CTC detection and isolation [8]. The most commonly employed strategy relies on epithelial lineage-specific markers such as EpCAM [9] or on size differences relative to PBMCs [10]. The only FDA-approved CTC assay uses an immunomagnetic separation technique based on the expression of epithelial surface markers [11,12]. The relatively low sensitivity of the assay, coupled with the requirement for pre-fixation makes the isolates unsuitable for molecular analysis beyond immunofluorescence. The dependence on marker expression does not allow for comprehensive detection of the heterogeneous CTC pool. It is also known that not every CTC will result in a new metastatic lesion. The pool of CTCs is composed of live and actively metastasizing cells and bystanders that are passively shed into the circulation [5,13–15], in combination with apoptotic tumor cell debris [16–18]. Alternative CTC detection strategies are needed, to isolate the metastasizing fraction, which is most likely to be found in the live CTC pool.

To develop a cost-effective method to identify live CTCs, we assessed the feasibility of using a group of synthetic near infrared (NIR) heptamethine carbocyanine dyes. We have previously demonstrated that these organic dyes are specifically transported into tumor cells and can distinguish malignant from nonmalignant cells in xenograft models or spontaneous tumors in vivo, and in surgical tumor specimens in vivo or ex vivo [19,20]. These dyes are taken up and accumulated by cancer cells through an active transport system independent of the conventionally employed epithelial surface marker (EpCAM). Furthermore uptake of the dye requires active (ATP-driven) transport and thus can be viewed as a functional assay for tumor cell viability. The results from the current study suggest that IR-783, the prototype of this group of selected NIR dyes, can be incorporated into several detection protocols to identify live CTCs. These live CTCs could be isolated from cancer patients prior to and during therapeutic intervention given the relatively non-invasive means of procurement. Further molecular interrogation could then ensue even at the single-cell level [21].

Materials and Methods

Antibodies and Reagents

Fluorescein isothiocyanate (FITC)-conjugated mouse monoclonal antibody (mAb) to human EpCAM (clone 9C4) and phycoerythrin (PE)-conjugated mouse mAb to CD45, together with purified isotype-matched IgG1 and IgG2b, were purchased from BioLegend (San Diego, CA). The source and use of other antibodies has been previously reported, including those against human RANKL, HIF-1α, NRP-1, and VEGF, as well as those to phosphorylated c-MET and the p65 subunit of NFκB [22]. The sources and purification of heptamethine carbocyanine dyes have been reported previously [19,20]. Ficoll-Paque PREMIUM 1.084 was purchased from GE Healthcare (Piscataway, NJ), and Histopaque-1077 was purchased from Sigma-Aldrich (St. Louis, MO).

Cell Culture

Human PC-3 cells were obtained from American Type Culture Collection (Manassas, VA). The cells were cultured in RPMI-1640 medium supplemented with 5% fetal bovine serum (FBS, Gemini Bio-Products, West Sacramento, CA), penicillin (100 unit/ml) and streptomycin (100 μg/ml). Cells were detached with 0.05% trypsin/EDTA (Invitrogen, Carlsbad, CA), washed in Ca²⁺- and Mg²⁺-free phosphate buffered saline (PBS, Invitrogen), and resuspended in complete culture medium. Cells were counted on a TC10 Automated Cell Counter (Bio-Rad, Hercules, CA), with trypan blue exclusion to confirm cell viability.

Clinical Blood Specimens

Patient blood samples were used with written informed consent through Cedars-Sinai Medical Center institutional review board-approved bio-banking protocols (IRB #Pro00025217 and #Pro00030418). Clinical blood samples were collected pre-operatively from 40 PCa patients undergoing radical prostatectomy at Cedars-Sinai Medical Center. Multiple blood samples were obtained from repeated visits of 5 patients with androgen independent disease. Additional blood samples from 34 healthy male donors aged between 32 and 70 years were obtained. About 7.5 ml of venous blood was collected into an EDTA-containing lavender top tube (BD, Franklin Lakes, NJ), and centrifuged at 1,500 rpm for 20 minutes at room temperature on a Heraeus CLINIFUGE centrifuge (Thermo Scientific, Logan, UT). After the plasma fraction was harvested for diagnostic purposes, the packed blood cell fraction was transported on ice to the research laboratory within 3 hours of collection.

Isolation of PBMCs

PBMCs were isolated with standard density gradient centrifugation. The packed blood sample was diluted with an equal volume of a balanced salt solution containing 0.01% glucose (w/v), 5 μM CaCl₂, 9.8 μM MgCl₂, 540 μM KCl, 126 mM NaCl, and 14.5 mM Tris, pH 7.6. A 2-ml aliquot of the diluted sample was layered onto a 3 ml Ficoll-Paque cushion and subjected to centrifugation at 400×g at room temperature for 40 minutes. Cells in the nucleated cell fraction were collected and washed twice in PBS, and resuspended in RPMI-1640 medium containing 5% FBS for further analyses.

Tumor Cell Spiking and Staining

Aliquots of the PBMCs were made so that each contained an equivalent number of cells from 1 ml donor blood, about 2×10⁶ cells/aliquot. To spike with cancer cells, known numbers of live PC-3 cells in RPMI 1640 medium containing 5% FBS were added to the PBMC aliquot. In control studies spiked with dead cancer cells, PC-3 cells in single cell suspension were killed in 75% ethanol and recovered in the same medium. The spiked samples were then stained with 20 μM NIR dyes at 37°C for 30 minutes. After washing twice in PBS to remove free dyes, the cells were fixed in formalin for 10 minutes at room temperature, washed twice in PBS, and resuspended in 400 μl Cell Staining Buffer (BioLegend). To further stain for surface markers, the samples were incubated first with isotype IgG on ice for 10 minutes, and then reacted simultaneously with FITC-conjugated mAb to EpCAM and PE-conjugated mAb to CD45 for 20 minutes. The working ratio of the mAbs was 0.1 μg/10⁶ cells. After washing twice with the Cell Staining Buffer, the cells were stained with 4’,6’-diamidino-2-phenylindole (DAPI, Invitrogen) before being subjected to detection.
Detection of CTC with Fluorescence Activated Cell Sorting (FACS)

Two FACS instruments (BD Biosciences, MA) were used in the study. To isolate CTCs, a FACSIAria III was used to sort positively labeled cells onto an APES-coated cytology slide (Bio-World, Dublin, OH). To enumerate CTCs, an LSRII Flow Cytometer was used. Manufacturer recommended detection procedures were followed. In parallel to the detection of each human blood sample, 1×10^6 PC-3 cells were used to spike a 1 ml aliquot of the sample. The flow cytometric profile of the spiked sample was used to guide the positivity gating. FACS data was further analyzed with FlowJo software.

Fluorescence Imaging

Stained cells isolated with the FACS sorter on slides were subjected to both fluorescence imaging and near infrared imaging with our previously reported procedure [19,20,22], with a Nikon Eclipse Ti fluorescence microscope excited by a xenon arc light source. Near infrared images were acquired through an INDO filter (780–840 nm).

Multiple Quantum Dot Labeling (mQDL)

Stained cells collected with the FACS sorter on glass slides were subjected to further staining with the mQDL protocol as previously reported [22]. In brief, the samples were first treated with stripping buffer to remove the mAb used for CTC isolation, and then subjected to successive staining with antibodies reacting to a group of PCA-related biomarkers, including RANKL, HIF-1α, NRP-1, VEGF, p-e-MET, and p-p65, as previously reported [22], with the same staining protocol. Finally, the samples were counterstained with DAPI before being subjected to spectral imaging and signal quantification on a CRI spectral imaging system with Nuance software (Caliper Life Sciences, Hopkinton, MA).

Statistical Analysis

Means, standard deviations, and medians were used to summarize continuous variables. Frequencies and percentages were calculated for categorical variables. Spearman correlations were calculated between continuous variables in the data due to skewed distributions. Comparisons of live CTC between categories of interest were done using Wilcoxon Rank Sum tests. A linear mixed model was used to assess the relationship between the number of cells spiked and retrieved, where the repeated measures of the donors were modeled with a heterogeneous compound symmetry covariance structure. All analyses were done using SAS version 9.3.

Results

We have previously demonstrated active uptake and retention of NIR dyes by cultured human PCA LNCaP, C4-2, PC-3, DU-145, ARCaPb and ARCaPM cells [19,20]. As few as ten PC-3 cells spiked into 1 ml human donor blood can be detected using IR-783. Dead PC-3 cells spiked in the same fashion failed to exhibit any IR-783 uptake. Because uptake of IR-783 requires the use of an ATP-requiring organic anion transporter, dye uptake itself is a functional assay which points toward tumor cell viability. To assess applicability of this approach to detecting live CTCs in patient blood samples, we incorporated NIR dye staining into FACS analysis. The widely used EpCAM/CD45 profile [9,12] was adopted to consolidate the CTC nature of the detected NIR+ cells.

1. Identification and Isolation of Live (NIR+) Cells from Human Blood

Patient blood samples were subjected to gradient centrifugation then sequential staining: first with NIR dye to stain live CTCs, then with fluorescence-labeled antibodies to EpCAM and CD45 for confirmation. Finally, the sample was stained with DAPI for the visualization of cell nuclei.

As a control to calibrate the performance of the detection system, we first tested the staining protocol with healthy donor blood spiked with PC-3 cells at varying numbers. In FACS analysis, the stained samples were sorted to isolate the EpCAM/CD45 population. These cells were then resorted to determine the number of NIR+DAPI+ cells (Figure 1A). PC-3 cells were identified as nucleated cells (DAPI+) expressing EpCAM but not CD45 (Figure S1). In repeated tests when the final EpCAM/CD45 NIR+DAPI+ counts were modeled as a function of spiked cell number, a significant increasing trend was observed with a correlation coefficient of 0.997 (Figure 1B and Table S1). The highly linear correlation suggested that this FACS protocol was usable for detecting CTCs with a negligible number of non-specific counts. We further determined that the recovered PC-3 cells on microscope slides could be readily seen by fluorescence microscopy (Figure 1C). Using the same protocol, we detected 2.8±1.7 EpCAM/CD45 NIR+DAPI+ events in a series of studies with blood specimens collected from 34 healthy donor subjects (Figure 1B). This detection was well in agreement with other studies on EpCAM+ cells in healthy donor blood samples analyzed using next generation CTC platforms [23], and probably reflects the background level of circulating epithelial cells. Importantly, in parallel studies where dead PC-3 cells were used in spiking, the EpCAM/CD45 NIR+DAPI+ counts were maintained at the background level, suggesting that the spiked dead PC-3 cells did not pick up the dye (data not shown). These control studies collectively demonstrate the suitability of NIR dye to stain and detect live CTCs.

2. Detection of Live CTCs in Patients with Localized PCA Undergoing Radical Prostatectomy

Using the functional FACS assay following NIR staining, we tested the detection of EpCAM/CD45+DAPI+ cells, henceforward referred to as total CTCs, in clinical PCA patients with emphasis on the EpCAM/CD45+NIR+DAPI+ events (henceforward referred to as live or NIR+ CTCs). PBMCs were isolated from pre-operative blood samples of 40 patients diagnosed with localized diseases. Detailed characteristics of these patients are summarized in Table 1.

This series of analysis revealed that live CTC counts varied remarkably among patients. EpCAM/CD45+NIR+DAPI+ counts ranged from 0 to 439 cells/ml (average 25 cells/ml; median 10 cells/ml) for this cohort of perioperative patients (Table 1). In this study, a count of less than 5 was considered normal, as our healthy donor pool had 2.8±1.7 EpCAM/CD45+NIR+DAPI+ counts (Figure 1B). The staining method reproducibly detected more than 5 live CTCs/ml in 30 of the 40 patients. Representative results from flow cytometric detection are shown in Figure 2A. We further demonstrated that the CTCs could be isolated directly onto microscope slides, and could be visualized with fluorescence microscopy (Figure 2B). In these analyses, live CTCs were distinguished from dead cells based on uptake of NIR dye (Figure 2B).

The live CTC counts detected from this cohort did not correlate significantly with pre-operative serum PSA level (r = 0.12, p = 0.47, Figure S2), pathologic N-stage (given only 1 node positive patient),...
Gleason score, or margin status (Figure S3). Comparing CTC counts to the Stephenson predictive monogram, there was no statistically significant relationship between live CTC counts and the Stephenson predictive monogram.

There were 10 patients with 5 or fewer live CTCs/ml (Table 1), and all had T2 disease with negative surgical margins. Only one of these patients (patient 26) had a detectable serum PSA concentration 2 weeks after radical prostatectomy. His serum PSA became undetectable later without additional intervention. The patient has since remained relapse-free. There were 3 patients with positive surgical margins (patients 2, 13, and 25, Table 1). These patients have also remained relapse-free for more than two years so far without additional anti-cancer therapies.

There were 3 patients had detectable serum PSA concentrations within 3 months after radical prostatectomy (Table 1). Patient 26 had a pT2cN0 Gleason 3+3 cancer with negative margins. Interestingly, he had only 3 live CTCs/ml blood. Serum PSA in this patient became undetectable later without additional intervention. Patient 29 had a pT3aN0 Gleason 4+3 cancer with positive margins, and was detected with 46 live CTCs/ml. His serum PSA level became undetectable after 6 months of androgen deprivation therapy that continues until this time. Patient 39 had lymph node metastasis at the time of surgery and was found to

![Figure 1. Calibrating the CTC detection method.](https://www.plosone.org/doi/10.1371/journal.pone.0088967.g001)
Table 1. Detailed summary of the patients undergoing prostatectomy.

| Patient ID | Gleason Score | T stage | N stage | Margin status | Stephenson prediction | Pre-operation PSA (ng/ml) | Post-operation PSA (ng/ml) | Total CTC (counts/ml) | NIR CTC (counts/ml) | Live CTC (%) |
|------------|---------------|---------|---------|---------------|------------------------|--------------------------|---------------------------|------------------------|-------------------|---------------|
| 1          | 3+3           | pT2a    | pN0     | –             | 98%                    | 4.76                     | <0.1                      | 8                      | 4                 | 50%           |
| 2          | 3+4           | pT2c    | pN0     | +             | 95%                    | 2.7                      | <0.1                      | 4                      | 2                 | 50%           |
| 3          | 3+4           | pT2c    | pN0     | –             | 98%                    | 1.9                      | <0.1                      | 15                     | 10                | 67%           |
| 4          | 3+4           | pT2c    | pN0     | –             | 96%                    | 4.6                      | <0.1                      | 26                     | 19                | 73%           |
| 5          | 3+4           | pT2c    | pNx     | +             | 117                     | 116                      | 99%                       | 117                    | 116               | 99%           |
| 6          | 3+3           | pT2c    | pN0     | –             | 98%                    | 4.5                      | <0.1                      | 10                     | 10                | 100%          |
| 7          | 3+3           | pT2c    | pN0     | +             | 97%                    | 4.33                     | <0.1                      | 12                     | 10                | 83%           |
| 8          | 3+4           | pT2c    | pN0     | –             | 116                     | 116                      | 99%                       | 116                    | 116               | 99%           |
| 9          | 3+4           | pT2c    | pN0     | –             | 96%                    | 4.54                     | <0.1                      | 34                     | 8                 | 24%           |
| 10         | 3+4           | pT2c    | pN0     | –             | 96%                    | 5.2                      | <0.1                      | 10                     | 10                | 100%          |
| 11         | 3+3           | pT2c    | pNx     | –             | 97%                    | 9.16                     | <0.1                      | 1                      | 1                 | 100%          |
| 12         | 3+4           | pT2c    | pN0     | –             | 96%                    | 4.9                      | <0.1                      | 2                      | 2                 | 100%          |
| 13         | 3+4           | pT2c    | pN0     | +             | 93%                    | 5.9                      | <0.1                      | 8                      | 5                 | 63%           |
| 14         | 3+4           | pT2c    | pN0     | –             | 96%                    | 5                        | <0.1                      | 151                    | 148               | 98%           |
| 15         | 3+3           | pT2c    | pN0     | –             | 98%                    | 1.53                     | <0.1                      | 12                     | 11                | 92%           |
| 16         | 3+4           | pT2c    | pN0     | –             | 95%                    | 7.69                     | <0.1                      | 5                      | 5                 | 100%          |
| 17         | 3+3           | pT2c    | pNx     | +             | 97%                    | 4.35                     | <0.1                      | 8                      | 8                 | 100%          |
| 18         | 3+3           | pT2c    | pN0     | +             | 96%                    | 5                        | <0.1                      | 10                     | 10                | 100%          |
| 19         | 3+4           | pT2c    | pN0     | –             | 94%                    | 14.02                    | <0.1                      | 21                     | 20                | 95%           |
| 20         | 3+4           | pT2c    | pN0     | –             | 95%                    | 7                        | <0.1                      | 23                     | 13                | 57%           |
| 21         | 3+3           | pT2c    | pN0     | –             | 97%                    | 7.3                      | <0.1                      | 54                     | 53                | 98%           |
| 22         | 3+4           | pT2c    | pN0     | +             | 95%                    | 2.79                     | <0.1                      | 117                    | 116               | 99%           |
| 23         | 3+4           | pT2c    | pN0     | –             | 95%                    | 5.7                      | <0.1                      | 0                      | 0                 | 0%            |
| 24         | 3+3           | pT2c    | pN0     | –             | 96%                    | 16.44                    | <0.1                      | 26                     | 26                | 100%          |
| 25         | 3+4           | pT2c    | pN0     | –             | 96%                    | 4.26                     | <0.1                      | 6                      | 5                 | 83%           |
| 26         | 3+3           | pT2c    | pNx     | +             | 96%                    | 4.02                     | 0.14                      | 3                      | 3                 | 100%          |
| 27         | 3+4           | pT3a    | pN0     | +             | 85%                    | 5                        | <0.1                      | 119                    | 87                | 73%           |
| 28         | 3+4           | pT3a    | pN0     | –             | 89%                    | 6.1                      | <0.1                      | 16                     | 11                | 69%           |
| 29         | 4+5           | pT3a    | pN0     | +             | 34%                    | 33                       | 0.43                      | 57                     | 46                | 81%           |
| 30         | 4+3           | pT3a    | pN0     | –             | 79%                    | 4.85                     | <0.1                      | 14                     | 13                | 93%           |
| 31         | 3+4           | pT3a    | pN0     | –             | 90%                    | 4.2                      | <0.1                      | 53                     | 48                | 91%           |
| 32         | 3+4           | pT3a    | pNx     | +             | 84%                    | 6.09                     | <0.1                      | 22                     | 10                | 45%           |
| 33         | 4+3           | pT3a    | pN0     | –             | 78%                    | 5.5                      | <0.1                      | 141                    | 132               | 94%           |
| 34         | 3+4           | pT3a    | pN0     | –             | 87%                    | 9.95                     | <0.1                      | 8                      | 7                 | 88%           |
| 35         | 3+4           | pT3a    | pN0     | –             | 89%                    | 5.6                      | <0.1                      | 8                      | 8                 | 100%          |
| 36         | 3+4           | pT3a    | pN0     | –             | 89%                    | 6.05                     | <0.1                      | 46                     | 43                | 93%           |
| 37         | 3+4           | pT3a    | pN0     | +             | 86%                    | 4.3                      | <0.1                      | 26                     | 19                | 73%           |
| 38         | 4+3           | pT3b    | pN0     | +             | 32%                    | 10                       | <0.1                      | 8                      | 7                 | 88%           |
| 39         | 4+3           | pT3b    | pN1     | +             | 15%                    | 12.6                     | 0.2                       | 440                    | 439               | 100%          |
| 40         | 3+3           | pTx     | pN0     | +             | 96%                    | 9.67                     | <0.1                      | 54                     | 48                | 89%           

Have high pre-operative CTC counts (439/ml). Additional cases of recurrence have to be examined in order to determine if pre-operation CTC counts could be used as a parameter for predicting disease relapse.

We also compared live CTC counts to surgical margin status. The 25 patients with negative margins had an average of 25 live CTCs/ml (range 0–148), in comparison to the 15 patients with positive margins that had an average of 54 live CTCs/ml (range 2–439). The difference was not statistically significant, likely due to the marked variation between individuals and the limited sample size.

While most of the patients in our cohort had Gleason 6 or 7 pathologies, no correlation was found between Gleason score and live CTC numbers. On the other hand, patients with higher live
CTC counts trended toward having more advanced disease by tumor staging. There was a significant association between live CTC counts and T stage, with pT3 patients having higher counts than pT2 cases (median 8 vs. 19, \(p=0.02\)). Notably, the only patient with node-positive pN1 disease had the highest live CTC count (439 CTCs/ml, patient 39, Table 1). High live CTC counts, therefore, seemed correlated to advanced tumor stages.

3. Assessments of Live CTCs in Patients with Metastatic Diseases

Consecutive blood samples were obtained from 5 PCa patients whose disease had relapsed and metastasized following initial therapy. These patients were undergoing various types of systemic treatment. In contrast to the live and total CTC counts in patients with localized disease, greater disparity between total and live CTC counts was seen (Table 2), while CTC counts across cases showed little correlation to serum PSA concentration (Figure 3). Nonetheless, when analyzed over time for individual patients, we identified interesting trends in which live CTC counts seemed to correlate inversely to the observed clinical benefit in response to therapies.

Patient 41 began bicalutamide treatment at the start of sample collection for metastatic castration-resistant PCa (mCRPC). He experienced asymptomatic biochemical (i.e., serum PSA) progression for two months, during which live CTC counts initially decreased but rebounded quickly. The treatment was changed to abiraterone acetate, which failed to produce a biochemical response. The patient developed symptomatic osseous metastatic disease and required radiation therapy. During disease progression, total CTC counts were sustained, but the live CTC proportion increased along with serum PSA level (Table 2 and Figure 3A).

Patient 42 was subjected to CTC detection before the first cycle of docetaxel therapy, which resulted in an excellent response judged by the continued drop of serum PSA level even after the therapy was ended. The patient remained asymptomatic for another 4 months before having to undertake another 8 cycles of docetaxel for symptomatic progression. During the treatment, the patient’s CTC counts decreased markedly, from 82 down to 6, and live CTCs decreased accordingly, from 37 to 0%. This patient experienced a rebound in total and live CTCs during the course of docetaxel treatment from day-20 to day-139. Toward the end of docetaxel treatment (from day-102 to day-139), we observed live CTCs rebounding from 14 to 94% (Table 2 and Figure 3B).

Patient 43 initially received docetaxel therapy on which he displayed initial biochemical and clinical responses. The second cycle of docetaxel treatment, however, was followed by rapid disease progression with progressive clinical deterioration (i.e., worsening pain and weight loss) and a rise in serum PSA. We noted a dramatic elevation in the percentage of live CTCs (from 2% up to 97%) without substantial changes of total CTCs (ranged from 36 to 44). The patient expired over the next 2 months with rapid clinical deterioration. The live CTC count rose markedly along with the deterioration (Table 2).

Patient 44 was treated with bicalutamide for mCRPC. The treatment did not result in biochemical benefit but a precipitous drop in CTC counts from 1052 to 54 was noted. Despite this dramatic drop in total CTCs, however, the percentage of live CTCs did not change substantially remaining in the range of 63 to 88%. The CTC counts rose from 54 to 196 between day-25 to day-73 at the time when bicalutamide treatment was terminated. This patient required palliative radiation and a quaternary hormonal maneuver (Table 2).

Patient 45 had castration sensitive PCa and was subjected to intermittent androgen suppression therapy that had been initiated 4 months before the first CTC detection. Live CTC count was below the threshold of detection, in good agreement with the well-suppressed serum PSA concentration (Table 2). In this case, the subsequent rise of live CTC counts was 4 months earlier than the PSA rebound, which was later suppressed with androgen deprivation therapy. It is worth noting, however, that this patient had a high percentage of live CTCs (83–84%) despite hormonal suppression therapy.
4. Isolation of Live CTCs for further Molecular Characterization

NIR staining facilitated the identification and isolation of live CTCs from clinical blood samples (Figure 2). We tested the isolated CTCs to further investigate PCA-related molecular alterations. In one such investigation, CTCs in PCA patients were isolated based on EpCAM⁺CD45⁻NIR⁺DAPI⁺ staining. Protein expression in the CTCs was detected by mQDL and was performed to verify expression of a panel of protein biomarkers associated with PCA progression and metastasis that our group is actively studying [22]. These assays demonstrated that the abnormal expression of RANKL, HIF-1α, NRP-1 and VEGF proteins seen in clinical PCA tumor specimens [22] could be easily detected in the isolated CTCs (Figure 4A). Similarly to clinical tumors, enhanced phosphorylation of c-Met, as well as the p65 subunit of the NFκB, was detected in the same CTC population. Intriguingly, signal quantification of the stained CTCs revealed remarkable intercellular heterogeneity, as individual proteins were detected with varied levels among CTCs (Figure 4B). Further investigation, however, is needed to assess the extent of CTC heterogeneity at the gene expression level.

Discussion

We developed a protocol for assessing the presence of live CTCs based on the active uptake of prototype IR-783 heptamethine carbocyanine dye [19,20]. In combination with antibodies to EpCAM, IR-783 staining identified live human PC-3 cells spiked into healthy donor blood with high reproducibility and correlation coefficient (Figure 1). We have determined that active transport of IR-783 into tumor cells can be used as a functional assay to demonstrate tumor cell viability (Figure 2B). This finding is further emphasized by the lack of IR-783 dye uptake in dead tumor cells (freeze-thaw and/or ethanol fixed) spiked into healthy donor blood (data not shown). We successfully detected and isolated live CTCs from clinical samples of primary PCa (Figure 2 and Table 1) and mCRPC patients (Figures 3 and Table 2). In a proof-of-concept study, the isolated live CTCs were amenable to multiplex detection of protein levels at the single cell level in freshly isolated CTCs using an mQDL method (Figure 4). The results collectively suggest that: 1) IR-783 staining can differentiate live CTCs from a total enumerated CTC population in a given patient in real time; 2) Correlations between the percentage of live CTCs and the development of progressive and therapeutic-resistant disease may be established; and 3) Isolated CTCs are appropriate for biological analysis such as mQDL analysis for protein expression at the single cell level. Our results provide for the first time a novel way of characterizing and even enumerating live CTCs in freshly harvested patient blood. This approach allowed us still to use techniques to characterize these live cells by quantifying protein expression in isolated CTCs.

Detection and characterization of CTCs have been technically challenging [24–26]. Conventional strategies have used either surface marker expression or cell size. At this time, new detection approaches are in development. EpCAM-decorated buoyant immune-microbubbles, for example, have been used to detect

| Table 2. Summary of metastatic prostate cancer patients. |
|-----------------------------------------------|
| Patient ID | Day of analysis | Clinical information | Therapy | PSA (ng/ml) | Total CTC/ml | NIR⁺CTC/ml | Live CTC (%) |
|-----------|----------------|----------------------|---------|------------|-------------|-----------|-------------|
| 41        | 0              | Starting bicalutamide| 27.1    | 44         | 36          | 82%       |
| 28        |                |                      | 30.7    | 38         | 3           | 8%        |
| 55        |                | Starting abiraterone | 44.1    | 31         | 22          | 71%       |
| 89        |                |                      | 68.9    | 49         | 13          | 27%       |
| 101       |                |                      | 89.3    | 54         | 32          | 59%       |
| 123       |                | Worsening bone pain  | Starting radiation | 124.8 | 36 | 32 | 89% |
| 42        | 0              | Starting docetaxel   | 293.7   | 82         | 30          | 37%       |
| 20        |                | Improved overall constitution | 243.3 | 6 | 0 | 0% |
| 41        |                |                      | 145.7   | 726        | 199         | 27%       |
| 62        |                |                      | 98.5    | 115        | 49          | 43%       |
| 80        |                |                      | 70.8    | 15         | 13          | 87%       |
| 102       |                |                      | 47.9    | 28         | 4           | 14%       |
| 123       |                |                      | 46.1    | 37         | 7           | 19%       |
| 139       |                | Ending docetaxel     | 32.8    | 18         | 17          | 94%       |
| 43        | 0              | Starting docetaxel   | 46.4    | 36         | 5           | 14%       |
| 36        |                | Progressive bone pain | 31     | 44         | 1           | 2%        |
| 51        |                | Systemic deterioration | Ending docetaxel | 31.8 | 39 | 38 | 97% |
| 44        | 0              | On bicalutamide      | 3.3     | 1052       | 922         | 88%       |
| 25        |                | Stopping bicalutamide | 7.3    | 54         | 35          | 65%       |
| 73        |                | Developing shoulder pain | Starting DES | 8.5 | 196 | 123 | 63% |
| 45        | 0              | On leuprolide for 6 months | 0.1 | 1 | 0 | 0% |
| 27        |                | <0.1                 | 6       | 5          | 83%        |
| 55        |                | PSA 0.2 ng/ml in one month | <0.1 | 207 | 174 | 84% |

doi:10.1371/journal.pone.0088967.t002
both spiked and endogenous cancer cells from whole blood [27],
while cytokeratin has been tested as markers for CTC detection
individually [28], or in combination with the EpCAM protein
[29]. None of these approaches provides any information on the
viability of the CTCs. Although the current FDA-approved
detection platform can detect some CTCs [30], we and others
have found that this approach relatively insensitive and is unable
to detect all the inherently heterogeneous CTCs [31,32]. Using
IR-783 dye staining may circumvent heterogeneity of surface
marker expression on tumor cells by using a functional assay to
detect all the viable CTCs. CTC apoptosis is a common
phenomenon [16–18]. We previously determined that only live
cancer cells were capable of internalizing and accumulating the
class of IR-783 analogs, most likely through the organic anion
transporting peptides (OATPs) as carrier proteins [19,20,33–36].
Application of the NIR dye in CTC detection provides a simple
strategy for determining cell viability. In the current study, many
of the EpCAM$^{+}$CD45$^{-}$ counts could be anucleated as indicated
by the lack of DAPI stain (Figure 2A), likely representing cell
debris. Although live and total CTC counts seemed close in
perioperative samples, the live CTC counts detected from many
mCRPC samples were significantly less than the corresponding
total counts (Tables 1 and 2), indicating increased death of CTCs
in mCRPC cases undergoing anti-tumor therapy. In this regard,
this study has established a cost-effective protocol for total and live
CTC detection by direct staining of the cells in combination with
rapid FACS detection. This protocol shows potential for
evaluating the cytotoxic effects of anti-tumor reagents in real
time, during the clinical treatment process.

When different patients were statistically analyzed as a group,
this study did not detect a direct correlation between CTC counts
and disease progression. Interestingly, lacking of correlation was
also reported in another study on different stages of prostate
cancers, with an FDA-approved detection method [37]. An
important finding of the study is the uniqueness of the CTC
profile in individual patients. This is supported by the individual
relationships between the CTCs detected and the disease status
diagnosed in each patient (Table 1) and by the consistency
between the CTCs detected using the protocol and the therapeutic
response observed by the attending clinicians (Table 2). CTCs
represent a pool of specific types of cancer cells capable of
surviving in the blood stream despite the remarkable shear forces.
The total number of CTCs at any given time could represent the
dynamic equilibrium between tumor shedding and the clearance
of CTCs by apoptotic death. Live CTCs, by contrast, could
provide crucial information on resistance to therapy and to
physical stress during circulation. Live CTCs were found to
fluctuate particularly in mCRPC patients and changes can be seen
prior to PSA changes in patients (Figure 3 and Table 2). Moreover,
the population of CTCs generally shifted toward a
greater portion of live cells when systemic therapy was stopped
(Table 2). These observations strongly support the usefulness of
live CTC to monitor therapeutic efficacy. Presently, most of these
patient subjects are still under the care of the oncologist (EP) and

![Figure 3. Live CTC counts as an independent indicator of disease progression.](image)
urologists (MHTB, CSG, DYJ and HLK), and data on their clinical course continues to be collected. Follow-up data will be evaluated for the applicability of NIR dye-assisted live CTC detection.

The prototype NIR dye IR-783 is a promising agent for live CTC detection. Compared with the EpCAM-based method, IR-783 stain alone was frequently found to be able to detect more candidate CTCs from the same patient sample (data not shown). This finding is consistent with the problem that currently utilized EpCAM-based methods offer incomplete detection and do not capture the entire CTC population. As an initial study to evaluate applicability of the IR-783 dye for CTC detection, we resorted to vestigial EpCAM expression as a reference to confirm the epithelial origin of the IR-783 stained cells, since there were no

Figure 4. Isolating CTCs for further molecular characterization. Live CTCs from the first sample from patient 44 (Table 2) were isolated onto a microscope slide and subjected to mQDL staining for the status of a panel of proteins documented to relate to PCa progression. A, Spectral images from two representative CTCs are shown on the top two panels (8 images each that represent the expression level of RANKL, pc-Met, HIF-1α, pp65, NRP-1 and VEGF; 400×; bar = 50 μm). B, Quantification of spectral image intensities of the six proteins indicated in Panel A from five stained cells from the same patient. The relative level of gene expression was calculated based on the expression of HIF-1α which was assigned as 1.0. doi:10.1371/journal.pone.0088967.g004
surface markers specific for CTCs. It is possible that a significant fraction of tumor cells may undergo extensive morphologic and behavioral changes to become migratory and invasive through epithelial to mesenchymal transition, resulting in CTCs with marked suppression or loss of EpCAM expression. Conversely, it is also possible that certain PBMCs in PCa patients have acquired the capacity for NIR dye uptake and retention, and the abnormal NIR staining of patient PBMCs is a sign of cancer progression. Additional investigation is warranted to identify the nature of NIR+ cells in patient blood.

In summary, we have established a novel method for identifying live CTCs from clinical samples. This method was demonstrated to be rapid, sensitive and highly efficient in distinguishing live CTCs from clinical samples. This method was demonstrated to be rapid, sensitive and highly efficient in distinguishing live CTCs from clinical samples. The method was shown to be changing dynamically in response to therapeutic intervention. Compared to other diagnostic parameters such as serum PSA, alterations in total CTCs and percentage of live CTCs, which are shown to be changing dynamically in response to therapeutic intervention. Compared to other diagnostic parameters such as serum PSA, alterations in total CTCs and percentage of live CTCs, which are shown to be changing dynamically in response to therapeutic intervention.

Further modification of these methods for high-throughput analysis tools: MHTB CSN DYJ BK HLK EMP. Wrote the paper: CS CPL MT HEZ LWKC RXW EMP. Contributed reagents/materials/analysis tools: MHTB CSN DYJ BK HLK EMP. Wrote the paper: CS CPL MT HEZ LWKC RXW EMP. Contributed reagents/materials/analysis tools: MHTB CSN DYJ BK HLK EMP.

**Supporting Information**

**Figure S1**

Confocal staining of PC-3 cells with individual detection agents used in this study. A representative stain is shown. A. PC-3 cells stained with each individual detection agent were subjected to FACS analysis. In upper row, PC-3 cells stained by a mixture of mouse IgG1-FITC and IgG2b-PE were used as control.

**Table S1**

Detection of PC-3 cells spiked to donor blood.

**Author Contributions**

Conceived and designed the experiments: LWKC RXW EMP. Performed the experiments: CS PZH CYC LZ HEZ RXW. Analyzed the data: CS PZH CYC LZ HEZ RXW. Contributed reagents/materials/analysis tools: MHTB CSN DYJ BK HLK EMP. Wrote the paper: CS CPL MHTB CSN DYJ BK HLK EMP. Contributed reagents/materials/analysis tools: MHTB CSN DYJ BK HLK EMP. Contributed reagents/materials/analysis tools: MHTB CSN DYJ BK HLK EMP. Contributed reagents/materials/analysis tools: MHTB CSN DYJ BK HLK EMP.

**References**

1. Diaz-Cano SJ (2012) Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci 13: 1951–2011.

2. Poste G, Tseng J, Doll J, Greig R, Kiemman D, et al. (1982) Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc Natl Acad Sci U S A 79: 6574–6578.

3. Posadas EM, Kohn EC (2005) Tumor angiogenesis and metastasis: Biology and clinical experience. In: Hopkins WJ, Young RC, Markman M, Perez CA, Barakat R et al., editors. Principles and practice of Genecologic Oncology. Philadelphia, PA: Lippincott Williams & Wilkins. 75–91.

4. Robinson VL, Kaufman EC, Sokoloff MH, Rinker-Schaeffer CW (2004) The basic biology of metastasis. In: Keller ET, Chung EW, editors. The biology of skeletal metastasis. Norwell, MA: Kluwer Academic Publishers.

5. de Boon JS, Scher HI, Montgomery RB, Parker C, Miller MC, et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302–6309.

6. Morgan TM, Lung PH, Porter MP, Lin DW, Ellis WJ, et al. (2009) Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 15: 677–683.

7. Pantel K, Alix-Panabieres C (2012) The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov 2: 974–975.

8. Becker TM, Caireiro NJ, Lim SH, Toguela A, Kienel N, et al. (2013) New frontiers in circulating tumor cell analysis - a reference guide for biomolecular profiling towards translational clinical use. Int J Cancer. Oct 7. doi: 10.1002/ijc.28516. [Epub ahead of print].

9. Rao CG, Chiasee D, Doyle GV, Miller MC, Russell T, et al. (2005) Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 27: 49–57.

10. Williams A, Balic M, Datar R, Coen R (2012) Size-based enrichment technologies for CTC detection and characterization. Recent Results Cancer Res 195: 87–95.

11. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, et al. (2007) Technologies for CTC detection and characterization. Recent Results Cancer Res 195: 87–95.

12. Coumans FA, Ligthart ST, Uhr JW, Terstappen LW (2012) Challenges in the application of molecular marker design. Int J Mol Sci 13: 1951–2011.

13. Smerage JB, Budd GT, Doyle GV, Brown M, Paezdit C, et al. (2013) Monitoring apoptosis and Bid-2 on circulating tumor cells in patients with metastatic breast cancer. Mol Oncol 7: 680–692.

14. Schilling D, Todenhofter T, Hennemoller J, Schwerner C, Fehm T, et al. (2012) Isolated, disseminated and circulating tumour cells in prostate cancer. Nat Rev Urol. Jul 10. doi: 10.1038/nrurol.2012.1136. [Epub ahead of print].

15. Larson CJ, Moreno JG, Pienta KJ, Gross S, Repollet M, et al. (2004) Apoptosis of circulating tumor cells in prostate cancer patients. Cytochemistry A 62: 46–53.

16. Rossi E, Basso U, Coladini R, Zilio F, Piaciardi S, et al. (2010) M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res 16: 5233–5243.

17. Yang X, Shao C, Wang R, Chu CY, Hu P, et al. (2013) Optical imaging of kidney cancer with novel near infrared heptamethine carbocyanine fluorescent dyes. J Urol 189: 792–710.

18. Yang X, Shi C, Tong R, Qian W, Zhai HE, et al. (2010) Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res 16: 2035–2044.

19. Zhao L, Lu YT, Li F, Wu K, Hou S, et al. (2013) High-Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber-Embedded Microchip for Whole Exome Sequencing Adv Mater. March 26. DOI: 10.1002/adma.201205237. [Epub ahead of print].

20. Hu P, Chu GC, Zhu G, Yang H, Esolehri D, et al. (2011) Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PLoS One 6: e28670.

21. Karlsson M, Nilsson O, Thor M, Winquist O (2008) Detection of metastatic colon cancer cells in sentinel nodes by flow cytometry. J Immunol Methods 334: 122–133.

22. Hu B, Rochefort H, Goldkorn A (2013) Circulating tumor cells in prostate cancer. Cancers (Basel) 5: 1676–1690.

23. Alix-Panabieres C, Pantel K (2014) Technologies for detection of circulating tumor cells: facts and vision. Lab Chip 14: 57–62.

24. Harouali A, Kang Z, Zheng SY, Cao L (2013) Circulating tumor cells: Advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther. Oct 14. DOI: 10.1016/j.pharmthera.2013.10.004. [Epub ahead of print].

25. Shi G, Cui W, Benchimol M, Liu YT, Mattrey RF, et al. (2013) Isolation of rare tumor cells from blood cells with buoyant immuno-microbubbles. PLoS One 8: e58017.
28. Harb W, Fan A, Tran T, Danila DC, Keys D, et al. (2013) Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay. Transl Oncol 6: 528–538.

29. Watanabe M, Uehara Y, Yamashita N, Fujimura Y, Nishio K, et al. (2013) Multicolor detection of rare tumor cells in blood using a novel flow cytometry-based system. Cytometry A. Dec 10. DOI: 10.1002/cyto.a.22422. [Epub ahead of print].

30. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, et al. (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897–6904.

31. Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, et al. (2013) NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods 64: 144–152.

32. Farace F, Massard C, Vimond N, Drusch F, Jacques N, et al. (2011) A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 105: 847–853.

33. Ito A, Yamaguchi K, Tomita H, Suzuki T, Onogawa T, et al. (2003) Distribution of rat organic anion transporting polypeptide-E (oatp-E) in the rat eye. Invest Ophthamol Vis Sci 44: 4877–4884.

34. Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158: 693–705.

35. Svoboda M, Riha J, Wlcek K, Jaeger W, Thalhammer T (2011) Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr Drug Metab 12: 139–153.

36. Zair ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA (2008) Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 9: 597–624.

37. Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, et al. (2013) Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol 139: 753–763.